Mangoceuticals, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jacob D. Cohen
- Full Time Employees
- 3
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- 15110 North Dallas Parkway Dallas TX United States of America 75248
- IPO Date
- Mar 21, 2023
- CIK
- 0001938046
- Website
- mangoceuticals.com
- Similar Companies
- Business
- Mangoceuticals, Inc. (NASDAQ: MGRX) develops, markets, and sells men's and women's health and wellness products and services through secure telemedicine platforms under the MangoRx and PeachesRx brands; core offerings include erectile dysfunction treatments under the Mango brand, hair loss products under the Grow brand, hormone balance and replacement therapies including oral testosterone undecanoate under the Mojo and Prime brands, weight loss solutions under the Slim brand, and access to licensed pharmacies for prescription fulfillment and discreet shipping. The company operates primarily in the United States, connecting consumers to licensed healthcare professionals via its websites www.MangoRx.com and www.PeachesRx.com for telehealth consultations in areas such as ED, hair growth, hormone therapy, obesity management including Wegovy and Zepbound access, and emerging nutraceutical formats. Founded in 2021 and headquartered at 15110 Dallas Parkway, Suite 600, Dallas, Texas, Mangoceuticals functions as a subsidiary of Cohen Enterprises, Inc. with approximately three employees. Recent strategic developments include the April 2025 acquisition of Smokeless Technology Corp.'s intellectual property, formulations, and assets to enter the $3.1 billion oral pouch market for nutraceutical and pharmaceutical delivery, complemented by the appointment of industry veteran Tim Corkum, formerly of JUUL Labs and Philip Morris, to lead the pouch division; November 2025 partnerships with Eli Lilly and Novo Nordisk to provide affordable access to obesity drugs Zepbound and Wegovy; the launch of MangoRx Direct and PeachesRx Direct programs offering personalized telehealth care plans; and an earlier April 2024 acquisition of Intramont Technologie's patent portfolio for oral solutions targeting infections.
Company News
MGRX Stock Alert: Halper Sadeh LLC is Investigating Whether Mangoceuticals, Inc. is Obtaining a Fair Price for its Shareholders
Nuclea Energy, Enters into Definitive Agreement to Acquire Moltex Energy's Advanced Nuclear Technology Assets
Mangoceuticals Inc.'s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy's Advanced Nuclear Technology Assets
Mangoceuticals' Merger Partner, Nuclea Energy Inc., Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure
Nuclea Energy Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure
Mangoceuticals' Merger Partner, Nuclea Energy (“Nuclea”), Executes MOU with Utah Office of Energy Development
Nuclea Energy USA Inc. Announces MOU with Utah Office of Energy Development
Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination
Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination
Nuclea Energy Enters Definitive Business Combination Agreement with Mangoceuticals, Establishing a Path to a Nasdaq Public Listing to Advance the Morpheus Microreactor
Mangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology
Mangoceuticals (NASDAQ:MGRX) versus Lipocine (NASDAQ:LPCN) Financial Contrast
Head to Head Analysis: Lyell Immunopharma (NASDAQ:LYEL) & Mangoceuticals (NASDAQ:MGRX)
Mangoceuticals Stock Doubles After Texas Lawsuit
Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.
Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds
Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study
Mangoceuticals Stock Skyrockets 50% Friday: What's Driving The Rally?
Mangoceuticals Stock Surges On Early Success Of Subscription TRT Model
MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program